Company Announcement - SenesTech, Inc announces Joshua M Moss will join its Board of Directors [1] - Joshua M Moss is co-founder, Managing Director and Portfolio Manager at EAM Global Investors, a boutique investment firm with approximately $3 billion in assets under management [2] - He has over 20 years of experience in institutional investment management, with a proven track record in portfolio management, team leadership and global business development [2] - Previously held senior roles at Allianz Global Investors and began his career at Credit Suisse focusing on investment banking and equity research [3] - Holds an MBA in Finance from UCLA Anderson School of Management and a BA in History from University of California, San Diego [4] Business Outlook - SenesTech and its product Evolve are poised for growth in the coming year and beyond according to Mr Moss [5] - The company has the right team and product to drive this growth [5] Company Overview - SenesTech is committed to creating healthier environments through humane animal pest population management using fertility control [6] - The company is an expert in fertility control technologies and has pioneered products like ContraPest and Evolve [6] - ContraPest is the only EPA-registered contraceptive for both male and female rats [6] - Evolve is an EPA-designated minimum-risk contraceptive soft bait [6] - Both products are designed to integrate seamlessly into pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create cleaner cities, more efficient businesses and happier households with humane, effective and sustainable products [6]

SenesTech, Inc. (NASDAQ:SNES) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Robert Blum - Lytham Partners Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Operator Good day and welcome to the SenesTech Third Quarter Fiscal Year 2024 Financial Results Conference Call. All participants will be in a listen-only mode for the duration of the call. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | | ...

Exhibit 99.1 SenesTech Announces Third Quarter 2024 Financial Results Record Revenue and Margin Performance PHOENIX, Ariz., November 12, 2024. SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control products today announced financial results for the third quarter of 2024. ® Recent Highlights • Revenues of $1.4 million in the first nine months ...

Record Revenue and Margin PerformancePHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control® products today announced financial results for the third quarter of 2024.Recent Highlights Revenues of $1.4 million in the first nine months of 2024, an increase of 51% compared to the same period of 2023. Gross ...

Significantly Expanding Market Reach PHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), a leader in fertility control solutions for managing animal pest populations, is excited to announce a significant expansion in the distribution of its groundbreaking rodent birth control product. Evolve™ Rat and Evolve™ Mouse are now available on Walmart Marketplace, one of the largest and most trusted eCommerce platforms in the world.SenesTech developed its proprietary ...

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ETPHOENIX, Nov. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its third quarter 2024, ended September 30, 2024, after the market close on Tuesday, November 12, 2024. The Company has scheduled a conference call that same day, Tuesday, November 12, 2024, at 5:00 pm ET, to review the results.Third Quarter 2024 Conference Call DetailsDate and Time: Tuesday, November 12, 2024 ...

PHOENIX, Oct. 31, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), the leader in birth control to manage rodent pest populations, today announces the successful registration of Evolve™ in Hong Kong.A Sustainable and Humane Approach to Rodent ControlHong Kong welcomes Evolve™, an innovative, non-lethal rodent birth control solution designed to target rat infestations at their root. Unlike conventional methods, Evolve restricts rodent reproduction, offering an effective and humane way to manage infestatio ...

PHOENIX, Sept. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today it will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 11:00am ET on Tuesday, October 1, 2024. The we ...

PHOENIX, Aug. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today the closing of an exercise of certain existing warrants to purchase 505,502 shares of the Company's common stock at a reduced exercise price of $4.60 per share. In addition, the Company issued new warrants, as described below. The aggregate gross proceeds from the exercise of ...